Company News-Bio-Thera Solutions, Ltd.

STADA and Bio-Thera receive European Marketing Authorization for Gotenfia, a Biosimilar to Simponi

2026-02-13

• European Commission grants approval for Gotenfia®, a golimumab biosimilar to Simponi® that was developed by Bio-Thera ...

查看详情

03-232026

Bio-Thera Solutions Announces Further Expansion of Partnership with Intas Pharmaceuticals for BAT2506, a Proposed Biosimilar Referencing Simponi® (golimumab), through Exclusive Commercialization and License Agreement in India

GUANGZHOU, China --- Bio-Thera Solutions (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline...
02-262026

Bio-Thera Solutions Announces NMPA Accepts New Drug Application for BAT4406F, an ADCC-enhanced fully humanized anti-CD20 monoclonal antibody

Guangzhou – Feb 26, 2025 – Bio-Thera Solutions, Ltd (688177:SH), a commercial-stage biopharmaceutical company developing...
02-132026

STADA and Bio-Thera receive European Marketing Authorization for Gotenfia, a Biosimilar to Simponi

• European Commission grants approval for Gotenfia®, a golimumab biosimilar to Simponi® that was developed by Bio-Thera ...

上一页 1 2 3 4 5 ··· 下一页